[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100446108":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":42,"responsibleParty":76,"collaborators":24,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":24,"enrollmentInfo":90,"targetDuration":24,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":24,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with chronic heart failure coming for scheduled day hospitalization","EXPERIMENTAL","* Clinical examination focusing on congestion\n* Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds\n* Blood sample retrieved for biological assessment and biobanking\n* Telephone follow-up",[13,14,15,16,17],"Procedure: Clinical examination centered on congestion","Procedure: Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography","Procedure: Blood sample retrieved for biological assessment and biobanking","Other: Telephone follow-up","Behavioral: Kansas City Cardiomyopathy Questionnaire (KCCQ)",[19,25,29,33,37],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Clinical examination centered on congestion","Clinical examination (including the EVEREST, ASCEND and Ambrosy scores) centered on congestion will be performed during day hospitalization or consultation",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Cardiac, pulmonary, peritoneal, jugular, renal Doppler ultrasounds and liver elastography","Cardiac, pulmonary, peritoneal, jugular and renal Doppler ultrasounds will be performed during day hospitalization or consultation\u002F peritoneal, jugular and renal Doppler ultrasounds and liver elastography are optional",[9],{"type":20,"name":30,"description":31,"armGroupLabels":32,"otherNames":24},"Blood sample retrieved for biological assessment and biobanking","Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization or consultation",[9],{"type":6,"name":34,"description":35,"armGroupLabels":36,"otherNames":24},"Telephone follow-up","Telephone follow-up will be performed 3, 12 and 24 months after visit (during day hospitalization or consultation)",[9],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":24},"BEHAVIORAL","Kansas City Cardiomyopathy Questionnaire (KCCQ)","Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge",[9],[43,63],{"facility":44,"status":45,"city":46,"state":24,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"CHRU de Nancy","RECRUITING","Vandœuvre-lès-Nancy","54500","France","FR",{"type":51,"coordinates":52},"Point",[53,54],6.17114,48.66115,{"lat":54,"lon":53},[57],{"name":58,"role":59,"phone":60,"phoneExt":61,"email":62},"Nicolas GIRERD, MD, PhD","CONTACT","+33383157322","+333","n.girerd@chru-nancy.fr",{"facility":44,"status":64,"city":46,"state":24,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"NOT_YET_RECRUITING",{"type":51,"coordinates":66},[53,54],{"lat":54,"lon":53},[69,73],{"name":70,"role":59,"phone":71,"phoneExt":72,"email":62},"Nicolas GIRERD, MD,PhD","+ 33 3 83 15 73 22","+ 33 3",{"name":74,"role":59,"phone":71,"phoneExt":72,"email":75},"Sanae BOUALI, PhD","s.bouali@chru-nancy.fr",{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Pr. Nicolas GIRERD","Principal Investigator","100446108","chronic-heart-failure---congestion-evaluation-100446108",false,"NCT05089149","Chronic Heart Failure - COngestion eValuation","Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)","CHF-COV","Inclusion Criteria:\n\n* Patients with chronic acute heart failure admitted in hospital for scheduled day hospitalization or consultation\n* Age ≥18 years\n* Patients having received complete information regarding the study design and having signed their informed consent form.\n* Patient affiliated to or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* Comorbidity for which the life expectancy is ≤ 3 months\n* Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \\\u003C15 ml\u002Fmin\u002Fm2 at inclusion.\n* History of lobectomy or pneumonectomy lung surgery\n* Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.\n* Pregnant woman, parturient or nursing mother\n* Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n* Adult person who is unable to give consent\n* Person deprived of liberty by a judicial or administrative decision,\n* Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.","ALL","18 Years",{"count":91,"type":92},200,"ESTIMATED","INTERVENTIONAL",[95],"NA","Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality \u002F integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.\n\nThe main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.",[98],"Chronic Heart Failure","2023-06-02",{"date":101,"type":102},"2023-06-05","ACTUAL",{"date":104,"type":102},"2021-12-14",{"date":106,"type":92},"2029-06-14",{"name":78,"class":6},2]